Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis

Recruiting Observational Study
Sepsis Trauma Injury
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Study type
Observational
Participants needed
450 (estimated)
Sponsor
University of Florida · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Sepsis participant: Inclusion Criteria: 1. age ≥18 years 2. meets criteria for sepsis/septic shock by Sepsis-3 consensus criteria. Exclusion Criteria: 1. have disease states that predispose to significant immune system dysfunction 2. have comorbidity burden or goals of care that preclude recover…
Contacts

Jennifer Lanz, MSN

352-273-5497

jennifer.lanz@surgery.ufl.edu

CONTACT

Ruth Davis, BSN

352-273-5897

ruth.davis@surgery.ufl.edu

CONTACT